Mirum Pharmaceuticals, INC

Mirum Pharmaceuticals announced FDA approval for Atebrioz to treat fibrodysplasia ossificans progressiva and positive Phase 3 results for brelovitug in chronic hepatitis delta.

Mirum Pharmaceuticals announced the appointment of Dr. Rob Myers as Chief Medical Officer, succeeding Dr. Joanne Quan, with Dr. Quan's departure effective October 19, 2026.

Mirum Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Mirum Pharmaceuticals announced the pricing of its $600 million offering of 0.00% Convertible Senior Notes due 2032, with net proceeds expected to be approximately $583.8 million.

Mirum Pharmaceuticals reported robust Q1 2026 results with increased net product sales and raised full-year guidance, alongside significant pipeline progress including a new drug application acceptance for zilurgisertib.

Mirum Pharmaceuticals announced its investigational drug volixibat met the primary endpoint in a Phase 2b study for primary sclerosing cholangitis (PSC), showing significant improvement in pruritus.

Mirum Pharmaceuticals announces a significant increase in product sales and substantial R&D investment in its Q1 2026 results.

Mirum Pharmaceuticals, Inc. reported a net income of $2.9 million for the third quarter of 2025, driven by significant increases in product sales, particularly Livmarli and Bile Acid Medicines.

Mirum Pharmaceuticals reports significant revenue growth and a substantial reduction in net loss for Q2 2025, driven by strong product sales and pipeline advancements.

Mirum Pharmaceuticals' Q1 2025 revenue increased significantly, driven by strong sales of Livmarli and Bile Acid Medicines, while the company continues to invest in its pipeline and commercial infrastructure.

Mirum Pharmaceuticals saw a significant increase in product sales in the third quarter of 2024, driven by both Livmarli and Bile Acid Medicines, though the company continues to operate at a net loss.

Mirum Pharmaceuticals saw a significant increase in revenue in the second quarter of 2024, primarily driven by sales of Livmarli and the newly acquired Bile Acid Medicines.

Mirum Pharmaceuticals, Inc. reported significant revenue growth in 2025, driven by its approved rare disease medicines, while actively expanding its clinical pipeline and navigating ongoing patent litigation.

Mirum Pharmaceuticals' 2024 10-K filing highlights increased product sales, ongoing clinical trials, and strategic portfolio expansion in rare disease treatments.

Mirum Pharmaceuticals' 10-K filing details its common stock terms, business strategy, product pipeline, and financial agreements, highlighting its focus on rare and orphan diseases.

Eric Bjerkholt, CHIEF FINANCIAL OFFICER of Mirum Pharmaceuticals, Inc., sold 9,943 shares of common stock on September 11, 2026 for $98.37 per share.

Jolanda Howe, SVP, GLOBAL CONTROLLER of Mirum Pharmaceuticals, Inc., sold 658 shares of common stock on September 2, 2026 for $100.00 per share.

Christopher Peetz, CHIEF EXECUTIVE OFFICER and a Director of Mirum Pharmaceuticals, Inc., sold 30,000 shares of common stock on September 1, 2026.

Jolanda Howe, SVP, GLOBAL CONTROLLER of Mirum Pharmaceuticals, Inc., sold 40,000 shares of common stock on August 18, 2026 for $100.00 per share.

Eric Bjerkholt, CHIEF FINANCIAL OFFICER of Mirum Pharmaceuticals, Inc., sold 6,001 shares of common stock on August 11, 2026 for $99.90 per share.

Christopher Peetz, CHIEF EXECUTIVE OFFICER and a Director of Mirum Pharmaceuticals, Inc., sold 20,000 shares of common stock on August 10, 2026.

Mirum Pharmaceuticals has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation.

Mirum Pharmaceuticals has filed definitive additional materials related to its proxy statement with the SEC.

Mirum Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders on May 29, 2025, to elect directors, ratify the selection of Ernst & Young LLP as the independent registered public accounting firm, and conduct an advisory vote on executive compensation.

Mirum Pharmaceuticals has filed definitive additional materials related to its proxy statement with the SEC.

Mirum Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, in a hybrid format.

Frazier Life Sciences funds and affiliates updated their beneficial ownership in Mirum Pharmaceuticals, detailing recent share acquisitions and a merger-related stock issuance.

Frazier Life Sciences Public Fund increased its beneficial ownership in Mirum Pharmaceuticals, Inc. following a merger with Frazier Life Sciences Public Overage Fund.

Frazier Life Sciences entities and associated individuals have filed an Amendment No. 6 to their Schedule 13D for Mirum Pharmaceuticals, Inc., clarifying beneficial ownership attribution for certain funds.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 5,909,184 shares, representing 9.7% of Mirum Pharmaceuticals, Inc.'s common stock, as of June 30, 2026.

FMR LLC has disclosed beneficial ownership of 6.2% of Mirum Pharmaceuticals Inc.'s common stock as of June 30, 2026.

BlackRock Inc. has disclosed a beneficial ownership of 5.7% in Mirum Pharmaceuticals, Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Mirum Pharmaceuticals Inc. following an internal realignment.

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a 4.1% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of December 31, 2025.

Janus Henderson Group plc has disclosed an increased beneficial ownership of 10.6% in Mirum Pharmaceuticals, Inc. common stock.